This week in drug discovery (12-16 August)
News round-up for 12-16 August by DDW Senior Digital Content Editor Diana Spencer.
The chosen news highlights this week all feature advances in drug development in oncology indications and reflect the breadth of therapeutic approaches to cancer treatment.
The top stories:
Genetic causes of colorectal cancer revealed in new study
A new study has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC), providing unique understanding of its response to treatment.
CAR-T therapy for nasopharyngeal cancer enters Phase II trials
The US Food and Drug Administration (FDA) has approved a Phase II clinical trial for Biosyngen’s BRG01, an EBV-specific CAR-T cell therapy.
Lynparza and Imfinzi combination approved in the EU for endometrial cancer
AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain patients with primary advanced or recurrent endometrial cancer.
First claudin 18.2 biomarker targeted therapy licensed in Britain
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Astellas’ Vyloy (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody.
New data support antitumour drug misetionamide in ovarian cancers
New published data have demonstrated positive monotherapy results for misetionamide as well as synergistic activity with PARP inhibitors (PARPis) and bevacizumab antineoplastic in ovarian cancer.